


Search Results - Record(s) 1 through 12 of 12 returned.





Terms	Documents	
L3 and identity.clm.	12	

Prev Page Next Page Go to Doc#

First Hit

L4: Entry 1 of 12 File: PGPB Dec 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030228322

PGPUB-FILING-TYPE: new

DOCUMENT-IDENTIFIER: US 20030228322 A1

TITLE: Multifunctional monoclonal antibodies directed to peptidoglycan of gram-

positive bacteria

PUBLICATION-DATE: December 11, 2003

INVENTOR - INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Schuman, Richard F.	Gaithersburg	MD	US	
Kokai-Kun, John Fitzgerald	Frederick	MD	US	
Foster, Simon J.	Sheffield	MD	GB	
Stinson, Jeffrey R.	Brookeville	MD	US	
Fischer, Gerald Walter	Bethesda		US	

APPL-NO: 10/ 323903 [PALM]
DATE FILED: December 20, 2002

RELATED-US-APPL-DATA:

Application is a non-provisional-of-provisional application 60/343444, filed December 21, 2001,

INT-CL: [07] $\underline{A61}$ \underline{K} $\underline{39}/\underline{00}$, $\underline{A61}$ \underline{K} $\underline{39}/\underline{38}$

US-CL-PUBLISHED: 424/184.1 US-CL-CURRENT: 424/184.1

REPRESENTATIVE-FIGURES: NONE

ABSTRACT:

The present invention encompasses protective monoclonal antibodies that bind to peptidoglycan of Gram-positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and block nasal colonization by Gram-positive bacteria in vivo. The invention also provides human, humanized and chimeric antibodies. The invention also sets forth the heavy chain and light chain variable regions of an antibody within the invention.

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application is based on and claims the benefit of U.S. Provisional Application Ser. No. 60/343,444, filed Dec. 21, 2001 (Attorney Docket No. 07787.6004). The entire disclosure of this provisional application is relied upon and incorporated by reference herein. This application relates to U.S. patent application Ser. No. 09/097,055, filed Jun. 15, 1998, which is specifically

incorporated herein by reference, and to U.S. Patent Application Ser. No. 60/341,806, and the application entitled, Methods for Blocking or Alleviating Staphylococcal Nasal Colonization by Intranasal Application of Monoclonal Antibodies, filed herewith, and previously, on Dec. 20, 2001, and to U.S. Pat. Nos. 5,571,511 and 5,955,074, which are all specifically incorporated herein by reference.